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Introduction
Benign monoclonal gammopathies, often called 
‘monoclonal gammopathies of undetermined sig-
nificance’ (MGUS), occur in up to 1% of normal 
people over the age of 50, with age-increasing 
incidence up to 1.7% above the age of 70 and 6% 
above 90.1 Monoclonal gammopathies are how-
ever 10 times more frequent in patients with poly-
neuropathy than age-matched controls, and 10% 
of adults with acquired polyneuropathy have a 
monoclonal gammopathy.2,3 If the gammopathies 
are categorized into immunoglobulin G (IgG), 
IgA and IgM subclasses, the incidence of poly-
neuropathy among patients with IgM monoclonal 
gammopathy can be as high as 50%, implying 
that 50% of patients with IgM MGUS may have 
or develop polyneuropathy.3,4 The association is 
not therefore fortuitous; it is also of importance to 
neurologists because paraproteinemic polyneu-
ropathies comprise a potentially treatable group 
of autoimmune neuropathies, as proposed >35 
years ago.5
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Although paraproteinemic polyneuropathies can 
be seen in a setting of lymphoid malignancy such 
as myeloma, plasmacytoma, or Waldenström’s 
macroglobulinemia, most neuropathies recog-
nized first by neurologists occur in connection 
with MGUS. The term MGUS was coined by 
hematologists to denote that the gammopathy is 
‘of no significance’ when there is no hematological 
disease; in a patient with neuropathy however, 
MGUS is ‘of significance’ because, even if benign, 
the gammopathy may point to an immune associ-
ation possibly amenable to immunotherapy.5,6
The patients who have a demyelinating polyneu-
ropathy associated with IgG or IgA–MGUS 
behave like chronic inflammatory demyelinating 
polyneuropathy (CIDP) and the paraprotein is 
likely coincidental; in contrast, patients with poly-
neuropathy and IgM MGUS have distinct clin-
icopathologic and immunobiologic phenotypes. 
This review describes the clinical spectrum and 
highlights the progress in the immunopathogene-
sis and treatment of IgM–MGUS neuropathy, the 
most common paraproteinemic neuropathy.
Clinical spectrum
Patients with IgM–MGUS typically manifest 
symptoms associated with dysfunction or loss of 
large myelinated fibers, most often presented with 
slowly progressive distal paresthesias, prominent 
in the feet, and impaired balance. The disease 
progresses very slowly, leading to impaired pro-
prioception, sensory ataxia, unsteady gait, and a 
varying degree of distal muscle weakness, first 
seen in toe and foot extensors.4–6 A good number 
of patients have an action tremor prominent in 
the hands that is unrelated to impaired proprio-
ception.7,8 The clinical spectrum varies substan-
tially; some patients have only distal paresthesias 
and minimal gait imbalance that may not suffi-
ciently affect daily activities or cause disability 
that could be captured with disability scales, as 
discussed;9 others manifest sensory ataxia and 
impaired gait; and still others have a combination 
of sensorimotor deficits with slowly progressive 
proximal and distal weakness that along with sen-
sory ataxia, cause significant disability.6,9,10 Some 
patients may have subacute onset and faster 
disease course resembling CIDP with mixed 
features of demyelination and axonal loss.11 
Immunofixation electrophoresis reveals an IgM 
monoclonal spike that remains present through-
out the course, although at times becomes faint or 
temporarily undetectable; the total IgM may be 
normal, but is usually elevated three-to-five times 
above normal. The Cerebrospinal fluid (CSF) 
protein is often elevated. The IgM spike is also 
detected in the CSF and exhibits the same elec-
trophoretic mobility as in the serum, in spite of 
the high-molecular weight of IgM, probably gain-
ing access via the dorsal root ganglia that lack 
blood–CSF barrier or from a disrupted root–CSF 
barrier.12 Nerve-conduction studies demonstrate 
a uniformly slow conduction velocity with a rather 
characteristic prolonged distal motor and sensory 
latencies, indicative of distal demyelination.13,14 
Sural nerve biopsy shows diminished numbers of 
myelinated axons with selective loss of large mye-
linating fibers, consistent with the clinical picture 
of impaired proprioception (Figure 1). Electron 
microscopy demonstrates a rather unique 
Figure 1. Cross-section of a sural nerve biopsy from a patient with immunoglobulin M antimyelin-associated 
glycoprotein antibody demyelinating polyneuropathy.
The biopsy specimen is stained with toluidine blue and shows selective loss of large-size myelinated fibers (left); histogram 
(right) depicting the fiber-size distribution of the patient’s nerve (yellow), overlapped with the fiber-size distribution (blue) 
from normal data, clearly demonstrating the selective loss of large-size fibers.
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splitting of the outer myelin lamellae, probably 
linked to the presence of IgM deposits in the same 
area of the split myelin sheaths.15
Clinical evaluation
The first goal is to ensure that the gammopathy is 
MGUS and not a sign of an underlying plasma cell 
dyscrasia, such as myeloma, plasmacytoma, or 
Waldenström’s macroglobulinemia. Monoclonal 
gammopathies are hematologically benign 
(MGUS) when the patients have: (a) <3 g/dl mon-
oclonal protein in the serum; (b) no signs of renal 
insufficiency, osteolytic or osteosclerotic lesions in 
the bone survey, and signs of anemia or hypercal-
cemia; (c) no suppression of the uninvolved (IgG, 
IgA) polyclonal (background) Igs; and (d) stable 
amount of the monoclonal protein in follow-up 
examinations.5,6,16 When ominous signs of malig-
nant plasma cell dyscrasia are detected, such as 
lytic bone lesions, Bence-Jones proteinuria, or 
progressively increased amount of monoclonal 
protein, a bone marrow examination is essential; 
the presence of >5% plasma cells and 12% lym-
phoid aggregates suggests malignancy. Because 
there is a 1% probability per year that MGUS may 
evolve into plasma cell dyscrasia,1 yearly follow-up 
examinations with immunofixation electrophoresis 
and Ig levels are necessary.16 Finding a free light 
chain should raise suspicion of amyloidosis derived 
from the variable region of the immunoglobulin 
light chain, mostly λ. Amyloid neuropathy is pain-
ful and often accompanied by autonomic symp-
toms, such as orthostatic hypotension, impotence, 
impaired gastric motility, or diarrhea. 
Diagnostically, deposits of amyloid may be found 
in the nerve and muscle biopsy, skin, abdominal 
fat or bone marrow.16
Immunopathogenesis
Antimyelin-associated glycoprotein antibodies
The main breakthrough in this neuropathy was the 
discovery by Latov and colleagues of IgM immuno-
reactivity to myelin-associated glycoprotein 
(MAG), a 100 kDa glycoprotein of the central and 
peripheral nerve myelin.17 Sera from approximately 
50% of these patients react with MAG or with 
acidic glycolipids that share antigenic determinants 
with MAG10,16–19 and reside in the carbohydrate 
component of the MAG molecule, as we have 
demonstrated by loss of reactivity after deglycosyla-
tion of purified MAG18 (Figure 2A). An important 
observation was the subsequent finding that the 
anti-MAG IgM coreacts with an acidic glycolipid 
in the ganglioside fraction of the human peripheral 
nerve, which by ion-exchange chromatography was 
seen between monosialotetrahexosylganglioside 
bearing one sialic acid (GM1) and  bearing  two 
sialic acids (GD1a) and identified as a SGPG19 
(Figure 2B). In contrast to MAG, which is present 
in both, the peripheral nervous system (PNS) and 
the central nervous system (CNS), SGPG is found 
exclusively in the peripheral nerves. SGPG also 
recognizes the human natural killer-1 (HNK-1) tri-
saccharide epitope, present on both MAG and 
other peripheral nerve glycoconjugates.20
Human anti-MAG antibodies can be detected in 
the patients’ sera with enzyme-linked immuno-
sorbent assay (ELISA) or Western blots by elec-
trophoresing purified MAG, isolated myelin, or 
whole brain homogenates.19,20 Because sera posi-
tive for anti-MAG antibodies almost always rec-
ognize the SGPG glycolipid, the assay has been 
performed by certain laboratories using SGPG as 
antigen instead of human MAG. It is clearly pref-
erable to use MAG instead of SGPG because the 
IgM antibodies bind to MAG 10–100 times more 
strongly than to SGPG; consequently, low-affinity 
anti-MAG antibodies may be missed if SGPG is 
used as antigen.16,19,20 In a large series of patients’ 
samples, the presence of MAG antibodies detected 
by ELISA was the most preferable assay because it 
was sensitive and easier than Western blotting.22
Other antiganglioside antibodies
In some patients with neuropathy clinically iden-
tical to IgM-anti-MAG phenotype, the serum 
may not react with MAG or SGPG, but only 
with various gangliosides most commonly those 
containing either a disialosyl moiety (e.g. GD1b, 
GQ1b, GT1b, the GalNac-GM1b, or Gal-NAc-
GD1a) or two gangliosides that share epitopes 
with GM2, a combination of GM2 and GM1, or 
GM1 and GD1b.21,23–25 Overall, more than half 
of the IgM paraproteins recognize MAG and 
SGPG, and 75% of the rest recognize ganglioside 
antigens, indicating that acidic glycolipids are the 
most common antigenic epitopes in immune-
mediated neuropathies, as depicted in Figure 
2C.21,23–26
Causal relationship between antimyelin-
associated glycoprotein/sulfoglucuronyl 
glycosphingolipid antibodies and the 
neuropathy
Because MAG is present only in small amounts 
in the peripheral nerves, compared with its 
Therapeutic Advances in Neurological Disorders 11
4 journals.sagepub.com/home/tan
Figure 2. Immunoreactivity of patients’ immunoglobulin M to myelin-associated glycoprotein and glycolipids.
(A) Immunoblots of sodium dodecyl sulfate gels with purified MAG extracted from rat (R) or human (H), are stained for 
protein with Am Bl (left) or immunostained with the serum of a patient with IgM MGUS neuropathy (middle lane). The 
patient’s IgM binds only to purified human MAG (middle lane; Per Neu); the reactivity is identical to the band obtained with 
a commercial MAb to human MAG (right) (from Dalakas16 and Ilyas et al19). (B) TLC overlay experiments show that the 
IgM from an anti-MAG-reacting patient recognizes glycolipid antigens of human peripheral nerve. The panel on the left 
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abundance in the CNS (which is spared in these 
patients), the immunoreactivity of IgM to MAG 
was considered by some as a nonpathogenic, 
binding to antigens with carbohydrate epitopes. 
The discovery of PNS-specific SGPG glycolipid 
however, that all anti-MAG-positive patients 
immunoreact with, has strengthened the view 
that glycolipids, along with glycoproteins, may 
be the primary antigenic targets.9,10,16,26,27 The 
following factors provide convincing evidence 
that these antibodies are causally related to the 
neuropathy:
(1) Sural nerve biopsies demonstrate deposition 
of IgM and complement on the myelinated nerve 
fibers,28 suggesting that activated complement is 
needed to induce demyelination.
(2) The patients’ IgM recognizes neural cell adhe-
sion molecules and co-localizes with MAG on the 
split myelin lamellae,15,16,26,27,29 implying involve-
ment of IgM in myelin disadhesion. This view is 
strengthened by observations on the patients’ skin 
biopsies which showed deposits of IgM, comple-
ment C3d, and MAG on the dermal myelinated 
fibers associated with reduction of intraneural 
nerve fiber density.29
(3) The patients’ whole serum or purified IgM, 
when injected with fresh complement into feline 
peripheral nerves, causes complement-dependent 
demyelination and conduction block within 2–9 
days.30
(4) Systemic administration of anti-MAG IgM 
paraprotein in chickens, causes segmental periph-
eral nerve demyelination with deposition of IgM 
on the outer myelin lamellae and splitting of the 
myelin sheath in a pattern similar to the one 
observed in the human neuropathy.31
(5) Immunization of cats with purified SGPG 
causes ataxic neuropathy, clinically resembling 
the anti-MAG/SGPG sensory ataxic phenotype, 
with inflammation within the dorsal root gangli-
onic neurons.32
Treatment
In patients with IgG or IgA MGUS who have an 
axonal neuropathy, the paraprotein is probably of 
unknown significance; if their neuropathy how-
ever is demyelinating, it should be treated as 
CIDP. In these patients, a causal relationship 
between the IgG or IgA MGUS and the neuropa-
thy has not been established because in contrast 
to IgM-MGUS, the A and G immunoglobulins 
do not recognize MAG or other antigens, except 
rarely when they recognize complex glycolipids, 
as shown in one of our patients with IgA 
gammopathy.33
Since the IgM-anti-MAG antibodies appear to 
exert a pathogenic effect on the myelin structure 
and function,34,35 it was expected that suppressing 
their production, removal of the antibodies or 
modification of the immune network should have 
a therapeutic effect. Unfortunately, this is not the 
case in clinical practice because conventional 
immunotherapies and chemotherapies offer mar-
ginal or transient benefit,26,27,35–42 necessitating 
the need for more specific therapies.
When to initiate therapy
The aforementioned clinical spectrum and dis-
ease severity should be taken into account in ther-
apeutic decisions. Patients who only have distal 
paresthesias without gait difficulties that affect 
daily activities, should be managed with support-
ive therapy consisting of exercise and balance 
shows resorcinol-stained ganglioside fractions isolated from human brain (CNS) or from human peripheral nerve (PNS). 
The prominent gangliosides are labelled for reference. The panel on the right shows an autoradiograph obtained from 
overlaying the same TLC plate with the patient’s serum followed by radiodinated antihuman IgM. The major glycolipid 
antigen recognized by the patients’ IgM (arrow) is SGPG found exclusively in the PNS. SGPG is between two minor glycolipid 
antigens (shown on the left gel) migrating above and below SGPG (from Dalakas16 and Ilyas et al.19). (C) Common glycolipids 
and their disialosyl moieties, consisting of NeuAca2-8NeuAc, that serve as antigens in autoimmune neuropathies The SGPG 
is most common in anti-MAG-neuropathy; the GM1 in MMN; the GD1a and GT1b with two sialic acid residues, and the GT1b 
immunoreact with 25% of MAG-reactive patients who have IgM-MGUS and ataxic neuropathy; the GQ1b ganglioside (with two 
disialosyl moieties) is the most specifc target antigen in Miller-Fisher syndrome (from Dalakas and Quarles21).
MAG, myelin-associated glycoprotein; Am Bl, amido black; IgM, immunoglobulin M; MGUS, monoclonal gammopathies of 
undetermined significance; TLC, thin layer chromatography; MAb, monoclonal antibody; RESO, resorsinol; CNS, central 
nervous system; PNS, peripheral nervous system; SGPG, sulfoglucuronyl glycosphingolipid; GM1, bearing one sialic 
acid; MMN, Multifocal Motor Neuropathy; GD1a, bearing  two sialic acids; GT1b, ganglioside with three sialic acids; GQ1b, 
ganglioside with four sialic acids.
Figure 2. (Continued)
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training. If, however, manifest gait ataxia, falls 
and muscle weakness, or present with a CIDP-
like picture from the outset, they should be treated 
early before permanent deficits due to axonal 
degeneration take place.36–42
Chemotherapeutic agents
Chlorambucil and prednisone, a combination 
used to treat Waldenström’s macroglobulinemia, 
can improve or stabilize a small number of 
patients, as we have witnessed in one,43 but the 
benefit is minimal and does not often outweigh 
the risks.37–42
Oral cyclophosphamide, in a randomized controlled 
trial of 35 patients (500 mg for 4 days) in combina-
tion with 60 mg prednisolone, every 4 weeks for 6 
months, showed some improvements in the Medical 
Research Council (MRC) sumscores,44 but meth-
odological problems with the study design and 
malignant transformation observed in 10% dimin-
ished the impact of the outcome.44
Fludarabine, applied to 16 patients in an open-
label study, showed transient benefits in some 
patients45,46 and significant adverse effects in 4.
Intravenous immunoglobulin
In three anti-MAG-positive patients we treated 
with intravenous immunoglobulin (IVIG),47 an 
improvement in motor and sensory functions was 
observed, prompting us to conduct the first con-
trolled study. Among 11 randomized patients, the 
neuropathy scores improved in three patients; the 
overall differences between IVIG and placebo were 
not however significant.48 A small multicenter 
study conducted in Europe, in spite of some meth-
odological issues, showed modest benefits that 
were statistically significant only for the secondary 
outcome measures.49,50 In an uncontrolled study in 
patients with sensory ataxic neuropathy associated 
with anti-GD1b, but not anti-MAG, antibodies, 
IVIG showed short-term benefits.51 Overall, the 
benefits from IVIG have been minimal.50
Rituximab: a promising anti-B-cell therapy for 
antimyelin-associated glycoprotein neuropathy
Rituximab is a monoclonal antibody against 
CD20, a B-cell surface antigen present on pre-B 
cells and throughout the B-cell life cycle, but not 
on plasma cells.52–54 Rituximab causes depletion 
of circulating B cells, prompting several trials.
Uncontrolled studies. First tried in a rather hetero-
geneous group of 21 patients, rituximab improved 
most patients 1 year after treatment and reduced 
IgM autoantibodies.55,56 In another, prospective, 
open-label study, six of nine patients improved after 
12 months with improved electrophysiology and 
reduced anti-MAG antibodies.57 Using double the 
standard dose (750 mg/kg every week for 1 month, 
instead of 375 mg/kg), the same authors noted 
improvement in four of eight additional patients.58 
Cumulative data from approximately 200 patients 
treated in the last 15 years show that rituximab 
helped 30–50% of the patients.36,59–63 In most, IgM 
levels decreased by 39% and anti-MAG by 68%.60
Controlled studies. In spite of the above promis-
ing observations, two controlled studies, using 
different scales and endpoints, have not convinc-
ingly captured this benefit. In the first double-
blind placebo-controlled study of 26 patients, 13 
were randomized to rituximab and 13 to pla-
cebo.64 The primary endpoint was a change of 
>1 in Inflammatory Neuropathy Cause and 
Treatment (INCAT) leg disability score at 
month 8. By intention-to-treat (ITT), 4/13 
(30%) of rituximab-randomized patients 
improved by >1 INCAT score, compared with 
0/13 placebo-receiving patients (p = 0.096). One 
of the patients randomized to rituximab however, 
was found to have a normal INCAT score 
at entry and could not improve; if this patient 
is excluded, the results become significant 
Figure 3. Effect of rituximab in the time to 10 m walk 
in a double-blind study.64
Difference in the 10 m walk time by repeated-measures 
analysis of variance between the rituximab and placebo 
groups. A significantly improved gait was seen in the 
rituximab group (yellow) compared with placebo (p = 0.042) 
(red) in the intention-to-treat analysis.
MC Dalakas
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(p = 0.036). The time to 10 m walk, a secondary 
endpoint, was significantly reduced in the rituxi-
mab-randomized group by ITT (Figure 3). On 
clinical grounds, walking and daily activities 
improved in 7/13 (53.8%) rituximab-treated 
patients, compared with 0/13 placebo-treated 
ones, reaching a percentage similar to the one 
observed in cumulative uncontrolled series, as 
mentioned earlier. The serum IgM was reduced 
by 34% and the anti-MAG titers by 50%64 
(Figure 4A–B). In this series, the most improved 
patients were those who had high anti-MAG 
titers and most severe sensory deficits. The main 
drawback of the study was the scales used; 
INCAT is a disability motor scale and could not 
effectively capture small functional changes in 
sensory function, especially mild gait impairment 
and sensory ataxia.
Important useful data regarding the immunobi-
ology of B cells and antibody production were 
observed in clinically-improved patients. 
Because the signs of clinical response coincided 
with depletion of B cells and reduction of anti-
MAG antibodies (Figure 4A–C), rituximab (that 
does not affect plasma cells), has likely depleted 
the memory B cells, which are the precursors of 
short-lived plasma cells. Indeed, the memory 
CD20+ CD27+ B cells were depleted 1 month 
after rituximab infusion and remained undetect-
able for 6 months; they started reappearing by 
month 8 and coincided with the slow rise of IgM 
serum level (Figure 4A–D). Study of B cell Ig 
gene usage between the four responders com-
pared with nonresponders, revealed clonal 
expansions of circulating IgM memory B cells 
that recognized MAG antigen.65 Most impor-
tantly, in the nonrituximab responders, the load 
of IgM memory B cells and the CDR3 clonally 
expanded sequences were higher and persisted 
before and after therapy, a finding we interpreted 
to suggest that low efficiency to reduce B-cell 
expansions may be associated with poor clinical 
response.65 Accordingly, higher doses of rituxi-
mab (as shown in patients who improved with 
double dosage),58 or more potent B-cell-
depleting agents that reduce further the clonally 
related autoreactive B cells may be more effec-
tive.36 A significant increase of Foxp3-positive 
immunoregulatory T cells was also observed at 8 
Figure 4. Reduction of B cells, immunoglobulin M, and antimyelin-associated glycoprotein after rituximab in a 
controlled study.
(A, B) The IgM levels are decreased by 34% (A) and the anti-MAG antibody titers by >50% (B), most prominently at month 
8, in rituximab-treated patients compared with placebo; (C, D) Kinetics of depletion and reappearance of CD20+ B cells (C) 
and the CD20+ CD27+ memory B cells (D) in rituximab-treated patients compared with placebo. B cells are depleted in the 
periphery by month 2 and start rebounding by month 6; the CD20+ CD27+ memory B cells start reappearing a little later by 
month 8 (D), often consistent with the need for reinfusion if there are early signs of clinical relapse.64
IgM, immunoglobulin M; MAG, myelin-associated glycoprotein; APC, antigen-presenting cell, PE, PRE (pre-B cells).
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months, suggesting that rituximab affected the 
immunoregulatory T-cell balance.64
A second, much larger controlled study, was con-
ducted in 54 patients, 26 randomized to rituxi-
mab and 28 to placebo.66 Using sensory scales as 
primary endpoint at month 12, the authors did 
not capture any benefit; they did, however, 
observe a significant response in secondary end-
points based on disability and time-to-walk 
scales.67 The discrepancy between the two well-
conducted clinical trials is obviously related to 
patient selection and scales used, highlighting the 
inadequacy of sensory INCAT to capture and 
quantify small, but clinically meaningful, changes 
related to gait ataxia.
Possible biomarkers of patient subsets 
responding to rituximab
Obviously, the question is not anymore whether 
rituximab is helpful or not, but why it benefits 
<50% of the patients and whether there are bio-
markers predicting response.36 Demyelinating 
pattern, absence of treatment and older age were 
significant risk factors for disability worsening,62 
while predominantly motor deficits and subacute 
progression were associated with positive 
response.11 Gender, ataxia, tremor and IgM anti-
MAG antibody titers were observed to be irrele-
vant in predicting response;11,60,62 in one study, 
recurrence of disease correlated best with high 
baseline anti-MAG titers and increasing anti-
MAG antibodies at follow up.63
Avidity, and variability in binding of anti-MAG/
SGPG antibodies to target antigens, is a factor 
possibly explaining different therapeutic 
responses.68 Serum levels of BAFF (B-cell activat-
ing factor), a key costimulatory molecule for B-cell 
survival, proliferation and immunoglobulin pro-
duction,52,54 were higher in anti-MAG patients not 
responding to rituximab;61 BAFF increased post 
rituximab in those who responded but, in those 
who relapsed, BAFF returned to baseline, suggest-
ing that BAFF may be useful in predicting 
responses and relapses.61 The finding that thera-
peutic efficacy depends on reconfiguration of 
memory B cells through sustained reduction of 
autoreactive clonal expansions,65 could also explain 
why rituximab is effective in only a patient subset. 
The need for retreatment to maintain stability in 
patients with prior response to rituximab may be 
monitored by the B27-memory B cells that start 
re-emerging after 8 months64 (Figure 4D).
Safety profile
Notwithstanding the benefit of rituximab for cer-
tain patient subsets, potential side effects should be 
considered.36,52,54 Rituximab may at times worsen 
anti-MAG neuropathy,69,70 a phenomenon we have 
also witnessed in three patients; this is probably 
related to immunomodulatory imbalance and 
release of proinflammatory cytokines that could 
possibly change the permeability of the blood–
nerve barrier allowing the influx of IgM antibodies 
within the nerve.36,70 This worsening is rare or self-
limited and is almost always reversed by IVIG. 
Rituximab has an excellent safety profile, but infec-
tions from common bacteria or viral agents can 
occur.36,52–54 Progressive multifocal leukoencepha-
lopathy has been reported in some patients with 
B-cell malignancies receiving rituximab plus chem-
otherapy (R-CHOP, fludarabine).36,52,54,71 
Vigilance is recommended, especially in patients 
receiving concomitant immunosuppressants.
The future: new drugs, better scales, and 
antigen-specific therapies
Anti-B-cell agents
If rituximab helps 30–50% of anti-MAG neu-
ropathy patients, the newer anti-B-cell agents 
that cause more profound or sustained B-cell 
depletion, could theoretically be more encour-
aging.36,52,54 B cells not only affect complement 
activation and antibody production but are 
strong antigen-presenting cells affecting 
autoregulation and T-cell activation,52,54 which 
explains the benefit of rituximab to diseases 
with dominant T-cell receptor gene usage.54,72 
Occrelizumab, the humanized version of rituxi-
mab that induces more complement activation, 
is approved for multiple sclerosis and should be 
considered. Ofatumumab that targets two dif-
ferent epitopes on CD20 causes more signifi-
cant B-cell depletion; it appears promising in 
multiple sclerosis (MS) and could be another 
candidate drug. Obinituzumab, a humanized 
monoclonal against CD20 approved for chronic 
lymphocytic leukemia, causes profound B-cell 
depletion; the drug, recently tried in two anti-
MAG neuropathy patients resistant or partially 
responding to rituximab did not show efficacy, 
in spite of reducing the IgM levels and 
anti-MAG titers.73 Belimumab against the 
B-lymphocyte stimulator BLyS, approved for 
lupus, may be another alternative, although its 
failure in MS and myasthenia gravis, lowers its 
priority status.36,54
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Scales
Because the disease exhibits a wide clinical spec-
trum, future studies should include patients with 
homogeneous clinical phenotypes and disease 
duration. Patients with very slowly progressing 
disease develop secondary axonal changes over 
time and worsening ataxia, with loss of ganglionic 
neurons; as a result, these patients are less likely 
to respond compared with patients having more 
recent disease and subacute progression.11 
Applying functional scales to capture even minor 
impairments in life activities, gait imbalance and 
hand tremors is fundamental. For example, in 
our controlled study,64 more patients were able to 
perform additional daily activities after rituximab 
compared with placebo, experienced steadier and 
faster walking, better balance, easier use of uten-
sils, and fewer falls, pain or paresthesias; none of 
these changes could be however numerically cap-
tured with the INCAT disability scales.64
Hand tremor
The tremor seen in many anti-MAG patients can 
be incapacitating. It is a neuropathic tremor, 
unrelated to impaired proprioception or a coex-
isting cerebellar disease; it is unresponsive to con-
ventional antiessential tremor drugs but can 
improve in some patients responding to immuno-
therapy. Unilateral thalamic deep brain stimula-
tion (DBS) applied in one patient unresponsive to 
plasma exchange, cyclophosphamide, steroids, 
primidone, and gabapentin, induced sustained 
improvement.73 DBS interferes with cerebellar 
circuits implicated in tremor generation; because 
in anti-MAG patients the cerebellum may receive 
disordered sensory input,75 DBS needs further 
study.
Antigen-specific therapy
Anti-MAG antibodies are thought to interfere 
directly with MAG’s involvement in adhesion 
and signaling processes at the axon–glia inter-
face76 resulting in cellular disadhesion. Because 
MAG has a higher HNK-1 epitope density than 
other myelin glycoconjugates leading to strong 
IgM antibody binding, removal of HNK with 
synthetized glycopolymers may prevent binding 
of anti-MAG IgM to human MAG.76 On this 
basis, in a mouse model for anti-MAG neuropa-
thy, the glycopolymer PL84(mimHNK-1), 
designed as an autoantibody scavenger by mim-
icking the natural HNK-1 glycoepitope, effec-
tively removed the pathogenic anti-MAG 
antibodies, offering promising potential for anti-
gen-specific immunotherapy.77
Funding
This research received no specific grant from any 
funding agency in the public, commercial, or not-
for-profit sectors.
Conflict of interest statement
The author declares that there is no conflict of 
interest.
References
 1. Kyle RA, Therneau TM, Rajkumar SV, et al. 
Prevalence of monoclonal gammopathy of 
undetermined significance. N Engl J Med 2006; 
354: 1362–1369.
 2. Kelly JJ, Kyle RA, O’Brien PC, et al. The 
prevalence of monoclonal gammopathy in 
peripheral neuropathy. Neurology 1981; 31: 
1480–1483.
 3. Kelly JJ. Peripheral neuropathies associated with 
monoclonal gammopathies of undetermined 
significance. Rev Neurol Dis 2008; 5: 14–22.
 4. Latov N, Hays A and Sherman WH. Peripheral 
neuropathy and anti-MAG antibodies. Crit Rev 
Neurobiol 1988; 3: 301–332.
 5. Dalakas MC and Engel WK. Polyneuropathy and 
monoclonal gammopathy: studies of 11 patients. 
Ann Neurol 1981; 10: 45–52.
 6. Dalakas MC. Pathogenesis of autoimmune 
neuropathies. Biochim Biophys Acta 2015; 1852: 
658–666.
 7. Dalakas MC. Chronic idiopathic ataxic 
neuropathy. Ann Neurol 1986; 19: 545–554.
 8. Dalakas MC, Teravinen H and Engel WK. 
Tremor as a feature of chronic relapsing and 
dysgammaglobulinemic polyneuropathies: 
incidence and management. Arch Neurol 1984; 
41: 711–714.
 9. Dalakas MC. Pathogenesis and treatment of 
anti-MAG neuropathy. Curr Treat Options Neurol 
2010; 12: 71–83.
 10. Latov N and Renaud S. Effector mechanisms 
in anti-MAG antibody-mediated and other 
demyelinating neuropathies. J Neurol Sci 2004; 
220: 127–129.
 11. Gazzola S, Delmont E, Franques J, et al. 
Predictive factors of efficacy of rituximab in 
patients with anti-MAG neuropathy. J Neurol Sci 
2017; 377: 144–148.
Therapeutic Advances in Neurological Disorders 11
10 journals.sagepub.com/home/tan
 12. Dalakas MC and Papadopoulos NM. 
Paraproteins in the spinal fluid of patients with 
paraproteinemic polyneuropathies. Ann Neurol 
1984; 15: 590–593.
 13. Kaku DA, England JD and Sumner AJ. 
Distal accentuation of conduction slowing in 
polyneuropathy associated with antibodies to 
myelin-associated glycoprotein and sulphated 
glucuronyl paragloboside. Brain 1994; 117(Pt 5): 
941–947.
 14. Lupu VD, Mora CA, Dambrosia J, et al. Median 
terminal Latency Index differentiates anti-MAG/
SGPG neuropathy from HMSN1. Muscle Nerve 
2007; 35: 196–202.
 15. Vallat JM, Tabaraud F, Magy L, et al. Diagnostic 
value of nerve biopsy for atypical chronic 
inflammatory demyelinating polyneuropathy: 
evaluation of eight cases. Muscle Nerve 2003; 27: 
478–485.
 16. Dalakas MC. Autoimmune peripheral 
neuropathies. In: Rich RR, Fleisher TA, Shearer 
WT, et al. (eds) Clinical immunology: principles and 
practice. 3rd ed. Oxford: Mosby Elsevier, 2008, 
pp.977–994.
 17. Latov N, Braun PE, Gross RB, et al. Plasma 
cell dyscrasia and peripheral neuropathy: 
identification of the myelin antigens that react 
with human paraproteins. Proc Natl Acad Sci USA 
1981; 78: 7139–7142.
 18. Ilyas AA, Quarles RH, McIntosh TD, et al. 
IgM in a human neuropathy related to 
paraproteinemia binds to a carbohydrate 
determinant in the myelin associated glycoprotein 
and to a ganglioside. Proc Natl Acad Sci USA 
1984; 81: 1225–1229.
 19. Ilyas AA, Quarles RH, Dalakas MC, et al. 
Polyneuropathy with monoclonal gammopathy: 
glycolipids are frequently antigens for IgM 
paraproteins. Proc Natl Acad Sci USA 1985; 82: 
6697–6700.
 20. Quarles RH. Myelin-associated glycoprotein 
(MAG): past, present and beyond. J Neurochem 
2007; 100: 1431–1448.
 21. Dalakas MC and Quarles RH. Autoimmune 
ataxic neuropathies (sensory ganglionopathies): 
are glycolipids the responsible autoantigens? Ann 
Neurol 1996; 39: 419–422.
 22. Kuijf ML, Eurelings M, Tio-Gillen AP, 
et al. Detection of anti-MAG antibodies in 
polyneuropathy associated with IgM monoclonal 
gammopathy. Neurology 2009; 73: 688–695.
 23. Ilyas AA, Li SC, Chou DKH, et al. Gangliosides 
GM2, IV4Gal NaC GM1B, and IV4Gal 
NaC GD1a as antigens for monoclonal 
immunoglobulin M neuropathy associated with 
gammopathy. J Biol Chem 1988; 263: 4369–
4373.
 24. Duane GC, Farrer RG, Dalakas MC, et al. 
Sensory neuropathy associated with monoclonal 
IgM to GD1b ganglioside. Ann Neurol 1992; 31: 
683–685.
 25. Quarles RH and Dalakas MC. Do antiganglioside 
antibodies cause human peripheral neuropathies? 
J Clin Invest 1996; 97: 1136–1137.
 26. Latov N. Pathogenesis and therapy of 
neuropathies associated with monoclonal 
gammopathies. Ann Neurol 1995; 37: S32–S42.
 27. Steck AJ, Stalder AK and Renaud S. Anti-myelin-
associated glycoprotein neuropathy. Curr Opin 
Neurol 2006; 19: 458–463.
 28. Monaco S, Bonetti B, Ferrari S, et al. 
Complement dependent demyelination in 
patients with IgM monoclonal gammopathy 
and polyneuropathy. N Engl J Med 1990; 322: 
844–852.
 29. Lombardi R, Erne B, Lauria G, et al. IgM 
deposits on skin nerves in anti-myelin-associated 
glycoprotein neuropathy. Ann Neurol 2005; 57: 
180–187.
 30. Willison HJ, Trapp BD, Bacher JD, et al. 
Demyelination induced by intraneural injection 
of human antimyelin associated glycoprotein 
antibodies. Muscle Nerve 1988; 11: 1169–1176.
 31. Tatum AH. Experimental paraprotein 
neuropathy, demyelination by passive transfer of 
human IgM anti-MAG. Ann Neurol 1993; 33: 
502–506.
 32. Ilyas AA, Gu Y, Dalakas MC, et al. Induction 
of experimental ataxic sensory neuronopathy 
in cats by immunization with purified SGPG. J 
Neuroimmunol 2008; 193: 87–93.
 33. Farrer RG, Dalakas MC and Quarles RH. 
Multiple antibodies to nerve glycoconjugates 
in an unusual patient with neuropathy and 
monoclonal IgA gammopathy. J Neuroimmunol 
1996; 66: 71–76.
 34. Vallat JM, Jauberteau MO, Bordessoule D, 
et al. Link between peripheral neuropathy and 
monoclonal dysglobulinemia: a study of 66 cases. 
J Neurol Sci 1996; 137: 124–130.
 35. Vallat JM, Magy L, Ciron J, et al. Therapeutic 
options and management of polyneuropathy 
associated with anti-MAG antibodies. Expert Rev 
Neurother 2016; 16: 1111–1119.
 36. Dalakas MC. Rituximab an anti-MAG 
neuropathy: more evidence for efficacy and 
MC Dalakas
journals.sagepub.com/home/tan 11
more predictive factors. J Neurol Sci 2017; 377: 
224–226.
 37. Magey L, Kabore R, Mathis S, et al. 
Heterogeneity of polyneuropathy associated with 
anti-MAG antibodies. J Neuroimmunol Res 2015; 
2015: 450391.
 38. Dalakas MC. Clinical Trials in CIDP 
and Chronic Autoimmune Demyelinating 
Polyneuropathies. J Peripher Nerv Syst 2012; 
(suppl 2): 34–39.
 39. Nobile-Orazio E, Meucci N, Baldini L, et al. 
Long-term prognosis of neuropathy associated 
with anti-MAG IgM M-proteins and its 
relationship to immune therapies. Brain 2000; 
123(Pt 4): 710–717.
 40. Leger JM, Guimaraes-Costa R and Muntean 
C. Immunotherapy in peripheral neuropathies. 
Neurotherapeutics 2016; 13: 96–107.
 41. Lunn MP and Nobile-Orazio E. Immunotherapy 
for IgM anti-myelin-associated glycoprotein 
paraprotein-associated peripheral neuropathies. 
Cochrane Database Syst Rev 2016; 10: CD002827.
 42. Steck AJ, Czaplinski A and Renaud S. 
Inflammatory demyelinating neuropathies and 
neuropathies with monoclonal gammopathies: 
treatment update. Neurotherapeutics 2008; 5: 
528–534.
 43. Dalakas MC, Flaum MA, Rick M, et al. 
Treatment of polyneuropathy in Waldenström’s 
macroglobulinemia: role of paraproteinemia 
and immunological studies. Neurology 1983; 33: 
1406–1410.
 44. Niermeijer JM, Eurelings M, van der Linden 
MW, et al. Intermittent cyclophosphamide with 
prednisone versus placebo for polyneuropathy 
with IgM monoclonal gammopathy. Neurology 
2007; 69: 50–59.
 45. Wilson HC, Lunn MP, Schey S, et al. Successful 
treatment of IgM paraproteinaemic neuropathy 
with fludarabine. J Neurol Neurosurg Psychiatry 
1999; 66: 575–580.
 46. Niermeijer JM, Eurelings M, Lokhorst H, 
et al. Neurologic and hematologic response 
to fludarabine treatment in IgM MGUS 
polyneuropathy. Neurology 2006; 67: 2076–
2079.
 47. Cook D, Dalakas M, Galdi A, et al. High-dose 
intravenous immunoglobulin in the treatment 
of demyelinating neuropathy associated with 
monoclonal gammopathy. Neurology 1990; 40: 
212–214.
 48. Dalakas MC, Quarles RH, Farrer RG, et al. A 
controlled study of intravenous immunoglobulin 
in demyelinating neuropathy with IgM 
gammopathy. Ann Neurol 1996; 40: 792–795.
 49. Comi G, Roveri L, Swan A, et al. A randomized 
controlled trial of intravenous immunoglobulin 
in IgM paraprotein associated demyelinating 
neuropathy. J Neurol 2002; 249: 1370–1377.
 50. Dalakas MC. The use of intravenous 
immunoglobulin in the treatment of autoimmune 
neurological disorders: evidence-based 
indications and safety profile. Pharmacol Ther 
2004; 102: 177–193.
 51. Attarian S, Boucraut J, Hubert AM, et al. 
Chronic ataxic neuropathies associated with anti-
GD1b IgM antibodies: response to IVIg therapy. 
J Neurol Neurosurg Psychiatry 2010; 81: 61–64.
 52. Dalakas MC. B cells as therapeutic targets in 
autoimmune neurological disorders. Nat Clin 
Pract Neurol 2008; 4: 557–567.
 53. Kosmidis M and Dalakas MC. Rituximab in the 
treatment of neurological disorders. Ther Adv 
Neurol Disord 2010; 3: 93–105.
 54. Alexopoulos H, Biba A and Dalakas MC. Anti-
B-Cell therapies in autoimmune neurological 
diseases: rationale and efficacy trials. 
Neurotherapeutics 2016; 13: 20–33.
 55. Levine TD and Pestronk A. IgM antibody-related 
polyneuropathies: B-cell depletion chemotherapy 
using rituximab. Neurology 1999; 52: 1701–1704.
 56. Pestronk A, Florence J, Miller T, et al. Treatment 
of IgM antibody associated polyneuropathies 
using rituximab. J Neurol Neurosurg Psychiatry 
2003; 74: 485–489.
 57. Renaud S, Gregor M, Fuhr P, et al. Rituximab in 
the treatment of polyneuropathy associated with 
anti-MAG antibodies. Muscle Nerve 2003; 27: 
611–615.
 58. Renaud S, Fuhr P, Gregor M, et al. High-
dose rituximab and anti-MAG-associated 
polyneuropathy. Neurology 2006; 66: 742–744.
 59. Benedetti L, Briani C, Grandis M, et al. 
Predictors of response to rituximab in patients 
with neuropathy and anti-myelin associated 
glycoprotein immunoglobulin. J Peripher Nerv 
Syst 2007; 12: 102–107.
 60. Benedetti L, Briani C, Franciotta D, et al. 
Long term effect of rituximab in anti-MAG 
polyneuropathy. Neurology 2008; 71:  
1742–1744.
 61. Benedetti L, Zardini E, Briani C, et al. B-cell-
activating factor in rituximab-treated patient with 
anti-MAG polyneuropathy. J Neurol Neurosurg 
Psychiatry 2011; 82: e1291–e1294.
Therapeutic Advances in Neurological Disorders 11
12 journals.sagepub.com/home/tan
 62. Galassi G, Tondelli M, Ariatti A, et al. Long-
term disability and prognostic factors in 
polyneuropathy associated with anti-myelin-
associated glycoprotein (MAG) antibodies. Int J 
Neurosci 2017; 127: 439–447.
 63. Campagnolo M, Zambello R, Nobile-Orazio E, 
et al. IgM MGUS and Waldenstrom-associated 
anti-MAG neuropathies display similar response 
to rituximab therapy. J Neurol Neurosurg 
Psychiatry. Epub ahead of print 13 May 2017. 
DOI: 10.1136/jnnp-2017-315736.
 64. Dalakas MC, Rakocevic G, Salajegheh M, et al. 
Placebo-controlled trial of rituximab in IgM 
anti-myelin associated glycoprotein antibody 
demyelinating neuropathy. Ann Neurol 2009; 65: 
286–293.
 65. Maurer MA, Rakocevic G, Leung CS, et al. 
Rituximab induces sustained reduction of 
pathogenic B cells in patients with peripheral 
nervous system autoimmunity. J Clin Invest 2012; 
122: 1393–1402.
 66. Léger JM, Viala K, Nicolas G, et al. Placebo-
controlled trial of rituximab in IgM anti-myelin-
associated glycoprotein neuropathy. Neurology 
2013; 80: 2217–2225.
 67. Ferfoglia R, Guimaraes-Costa R, Viala K, et al. 
Long-term efficacy of rituximab in IgM ant-
myelin-associated glycoprotein neuropathy: 
RIMAG follow-up study. J Peripher Nerv Syst 
2016; 21: 10–14.
 68. Weiss MD, Dalakas MC, Lauter CJ, et al. 
Variability in the binding of anti-MAG and 
anti-SGPG antibodies to target antigens 
in demyelinating neuropathy and IgM 
paraproteinemia. J Neuroimmunol 1999; 95: 
174–184.
 69. Broglio L and Lauria G. Worsening after 
rituximab treatment in anti-mag neuropathy 
[letter]. Muscle Nerve 2005; 32: 378–379.
 70. Vo ML, Martin P and Latov N. Correlation of 
changes in Gait parameters, with phenotype, 
outcome measures, and electrodiagnostic 
abnormalities in a patient with anti-MAG 
neuropathy after exacerbation and improvement. 
J Clin Neuromuscul Dis 2015; 17: 22–26.
 71. Bonavita S, Conforti R, Russo A, et al. Infratentorial 
progressive multifocal leukoencephalopathy in a 
patient treated with fludarabine and rituximab. 
Neurol Sci 2008; 29: 37–39.
 72. O’Hanlon TP, Dalakas MC, Plotz PH, et al. 
Predominant a/b T cell receptor variable and 
joining gene expression by muscle-infiltrating 
lymphocytes in the idiopathic inflammatory 
myopathies. J Immunol 1994; 152: 2569–2576.
73. Rakocevic G, Martinez A, Dalakas MC. 
Obinutuzumab (GAZYVA), a Potent Anti-B 
Cell Agent, in the Treatment of Rituximab-
Unresponsive IgM Anti-Myelin-Associated-
Glycoprotein (MAG)-Mediated-Neuropathy 
(submitted to the American Academy of 
Neurology annual meeting April 2018).
 74. McMaster J, Gibson G, Castro-Prado F, et al. 
Neurosurgical treatment of tremor in antimyelin-
associated glycoprotein neuropathy. Neurology 
2009; 73: 1707–1708.
 75. Weeks RA, Gerloff C, Dalakas MC, et al. PET 
study of visually and non-visually guided finger 
movements in patients with severe pan-sensory 
neuropathies and healthy controls. Exp Brain Res 
1999; 128: 291–302.
 76. Burger D, Perruisseau G, Simon M, et al. 
Comparison of the N-linked oligosaccharide 
structures of the two major human myelin 
glycoproteins MAG and P0: assessment of the 
structures bearing the epitope for HNK-1 and 
human monoclonal immunoglobulin M found in 
demyelinating neuropathy. J Neurochem 1992; 58: 
854–861.
 77. Herrendorff R, Hänggi P, Pfister H, et al. 
Selective in vivo removal of pathogenic anti-MAG 
autoantibodies, an antigen-specific treatment 
option for anti-MAG neuropathy. Proc Natl Acad 
Sci USA 2017; 114: E3689–E3698.
Visit SAGE journals online 
journals.sagepub.com/
home/tan
SAGE journals
